Deloitte AG

Colin Terry
Colin Terry
Partner, R&D Strategy and Operations 
Conference attendance
Biography

Colin is a Director and a key leader in our UK / Swiss Life Science practice. He has been with Deloitte since 2011 working in the US firm until 2014 when he moved to the UK.

Colin’s client advisory work in the Life Sciences sector ranges across strategy and operations focused on the R&D function including operating model development and implementation as well as post-merger integration (PMI). These engagements have been serving client Boards and their senior leadership teams in R&D, Commercial and Supply Chain

Colin is an author of our annual R&D productivity analysis study which reviews productivity of the worlds largest pharmaceutical businesses.

Recent engagements include leadership of the R&D integration workstream for a Med Tech merger leading the European team as well as global responsibility for the R&D and Manufacturing footprints; and design of a new Pharma vaccine R&D model post integration

Colin has a B.Sc (Hons). in Microbiology from the University of London, Queen Mary & Westfield and a Marketing Diploma from the Chartered Institute of Marketing. 

Murielle Launay
Senior Manager 
Conference attendance
Mrs Anna Samanta
Mrs Anna Samanta
Managing Partner 
Conference attendance
Biography

Anna leads Deloitte’s Integration & Separation Advisory (I&SA) team in Switzerland and the EMEA Centre of Excellence for Life Sciences I&SA. Anna is recognized as one of the foremost integration advisors in EMEA and has supported over 30 integrations and separations including many landmark deals. She provides advice and challenge to senior management and boards in planning and delivering complex cross-border integrations and operational carve outs.

John Feigl
Head of Debt & Rating Advisory Switzerland 
Conference attendance
Nico Kleyn
Partner 
Conference attendance

Drooms AG

Drooms is the leading provider of data rooms in Europe. The specialized software facilitates highly secure access to confidential documents, as well as the ability to exchange them safely with third parties beyond company firewalls. Drooms allows for the transparent, efficient and secure management of confidential business processes such as commercial real estate sales, mergers and acquisitions, NPL transactions and board communications. Drooms’ clients include the world's leading real estate companies, consulting and law firms and corporations such as METRO GROUP, Evonik, Morgan Stanley, JLL, JP Morgan, CBRE, Rewe and UBS.

Company Type
Sector
Jan Hoffmeister
Managing Director 
Conference attendance
Luisa Henk
Luisa Henk
Senior Manager Business Development 
Conference attendance

Novasecta Ltd. United Kingdom

Novasecta is a specialist management consulting firm for pharmaceutical companies. Novasecta’s clients are primarily CEOs, Commercial Heads and R&D Heads. We provide them with practical solutions based on a profound understanding of their unique businesses and their industry context. We deliver the strategic counsel, insight, and change that they need to drive performance improvement and sustainable growth.

Company Type
Keywords

Strategy

Business Development

R&D

Commercial

CEO

Consulting

Mr John Rountree
Mr John Rountree
Managing Partner 
Conference attendance
Biography

John has over 30 years of experience in management consulting and creating value with pharmaceutical and medical product companies.

He founded Novasecta in 2003 and has built the company by selecting and developing top quality consultants who work successfully with clients across R&D, corporate/business development and commercial disciplines. John has directed many strategic and management initiatives, achieving amongst others, strategic organisational change, major licensing deals, corporate transformation, optimised asset portfolios, and improvements in strategic partnerships.

Provectus Biopharmaceuticals, Inc. United States

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

Company Type
Company Ticker
[NYSE MKT: PVCT]
Year Founded
2002
Management Team

Timothy Scott, Ph.D. - President

Eric Wachter, Ph.D. - Chief Technology Officer

Peter R. Culpepper, CPA, MBA - Interim CEO & COO

John R. Glass, CPA - Interim CFO

Chresten Hedegaard
Consultant 
Conference attendance
Peter R. Culpepper
COO and Interim CEO 
Conference attendance
Biography

Pete Culpepper, CPA, MBA, has spent 20 years in the financial field working for a wide range of companies and industries in the U.S. and abroad, especially high-growth startups. His experience with for-profit companies ranges from private start-ups to publicly traded, global conglomerates. He also has worked with large non-profits and a national CPA accounting firm. He led the national operating unit of a $1 billion publicly traded telecommunications company, as well as numerous operating units in Eastern Europe for a global telecommunications company. He handled the capital reporting process for a $5 billion global construction project and the formation of systems for a division that grew $150 million in revenue in two years. Previous employers include Neptec, Inc., a privately held optical networking component manufacturer; Metromedia Companies; and PageNet, the largest wireless messaging company in the world. Culpepper taught undergraduate and graduate business courses for the University of Phoenix Online. He is licensed as a Certified Public Accountant in Maryland and Tennessee. His professional affiliations include the American Institute of Certified Public Accountants, Financial Executives International and the Financial Executives Networking Group. Culpepper holds a master's of business administration (MBA) in finance from the University of Maryland. He earned an AAS in Accounting from the Northern Virginia Community College - Annandale, Virginia. He earned a bachelor's degree in philosophy from the College of William and Mary.

Presentation Time and Location:
09:30 | Track C | 28th Sep
Valentina Koselâp
Conference attendance

Torreya Partners (Europe), LLC

Company Type
Chris Britten
Chris Britten
Managing Director 
Conference attendance
Biography

Chris Britten, Managing Director, Torreya Partners (Europe) LLP

Chris is a Managing Director at Torreya Partners, a leading global investment bank focused on facilitating partnerships, M&A transactions and financings in the pharmaceutical sector worldwide.  He joined Torreya from Sanofi Pasteur-MSD where he had responsibility for all business and corporate development activities.  He is also a Non-executive Director at Phico Therapeutics Ltd.

 

Prior to Sanofi Pasteur-MSD, Chris held positions at Astellas (Europe) in Business and Commercial Development and several years at Deloitte Corporate Finance where he headed up the Life Science Advisory practice assisting clients across the life science sector in a wide range of transactional activities (M&A, divestments, partnering, valuation, fund-raising).  Previously, Chris was at GlaxoSmithKline where he held roles of increasing responsibility in Business Development, Corporate Ventures and R&D.  He holds a PhD in Biochemistry and an MBA in Finance.

Mrs Stephanie Léouzon
Mrs Stephanie Léouzon
Partner and Head of Torreya Partners Europe 
Conference attendance
Biography

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. Previously she worked in healthcare investment banking in the US and Europe from 1989 to 2010, most recently at Credit Suisse in London as a Managing Director and Senior Advisor.

She has advised life sciences clients on more than 25 strategic transactions, valued at over
$65 billion, and has been involved in over 45 financing transactions to provide over $10 billion to healthcare clients.

Stephanie earned an MBA degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a BA degree, cum laude, from Mount Holyoke College in 1985.

Susan Clement-Davies
Managing Director 
Conference attendance